OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…Details
Speaker: Dr Andrew Chantry, Sheffield Teaching Hospitals NHS Foundation TrustDetails
Speaker: Mr Sean Molloy, Royal National Orthopaedic Hospital, LondonDetails
UKMF Autumn Day 2013: What do we know about myeloma in elderly patients from trials and observational studies?
Speaker: Prof Heinz Ludwig, Wilhelminenhospital, Vienna. AustriaDetails
Speaker: Dr Faith Davies, Royal Marsden Hospital and The Institute of Cancer Research, London.Details
Speaker: Dr Stella Bowcock, Princess Royal Hospital, OrpingtonDetails